首页> 外文期刊>Journal of nuclear medicine technology >Molecular Breast Imaging: Administered Activity Does Not Require Adjustment Based on Patient Size
【24h】

Molecular Breast Imaging: Administered Activity Does Not Require Adjustment Based on Patient Size

机译:分子乳腺成像:不需要根据患者人数调整管理的活动

获取原文
           

摘要

At our institution, molecular breast imaging (MBI) is performed with 300 MBq of 99mTc-sestamibi for all patients. For some nuclear medicine procedures, administered activity or imaging time is increased for patients of larger size to obtain adequate counts. Our objective was to assess whether uptake of 99mTc-sestamibi in the breast is influenced by patient size. Methods: Records from patients who underwent a clinical MBI examination between July and November 2016 were reviewed. Those in whom our standard injection and preparation techniques were followed were included in the analysis. Patients were injected with approximately 300 MBq of 99mTc-sestamibi. Residual activity was measured to allow calculation of exact administered activity for each patient. Breast images were acquired at 10 min/view using a dual-head cadmium zinc telluride–based γ-camera. Breast thickness was measured as the distance between the 2 detectors. Patient height, weight, body surface area, and body mass index were obtained from records. Lean body mass with the James equation (LBMJames) and Janmahasatian correction (LBMJanma) was calculated. Count density in the breast tissue was measured by drawing a region of interest around the central breast tissue of the right breast mediolateral-oblique view of the lower detector. Count density was expressed as cts/cm2/MBq of administered activity. Spearman correlation coefficient (rs) was calculated. Results: A total of 200 patients were analyzed. No dose infiltration was suspected at any injection. Average administered activity was 292 MBq (SD, 13.8 MBq; range, 247–326 MBq). Average count density was 7.2 cts/cm2/MBq (SD, 2.7 cts/cm2/MBq; range, 3.1–17.8 cts/cm2/MBq). MBI count density was weakly negatively correlated with height (rs = ?0.18; P = 0.01), weight (rs = ?0.23; p = 0.001), body mass index (rs = ?0.16; P = 0.02), body surface area (rs = ?0.22; P = 0.002), LBMJames (rs = ?0.23; P = 0.001), and LBMJanma (rs = ?0.23; P = 0.001). No correlation was observed between count density and breast thickness (rs = 0.06; P = 0.37). Conclusion: Our results suggest a lack of relationship between uptake of 99mTc-sestamibi in breast tissue and body size or compressed breast thickness. Altering from the standard 300 MBq of administered activity for larger patients is likely unnecessary.
机译:在我们的机构中​​,对所有患者使用300 MBq的99mTc-司他米比进行分子乳腺成像(MBI)。对于某些核医学程序,较大规模的患者增加了活动或成像时间,以获得足够的计数。我们的目标是评估乳房中99mTc-司他米的摄取是否受患者人数的影响。方法:回顾了2016年7月至2016年11月间进行了MBI临床检查的患者的记录。分析中包括遵循我们标准注射剂和制备技术的患者。为患者注射了约300 MBq的99mTc-司他米比。测量残余活性以允许计算每个患者的确切给药活性。使用双头碲化镉锌基γ相机以每分钟10分钟的速度获取乳房图像。乳房厚度测量为两个检测器之间的距离。从记录中获得患者身高,体重,体表面积和体重指数。用James方程(LBMJames)和Janmahasatian校正(LBMJanma)计算瘦体重。乳腺组织中的计数密度是通过绘制下检测器右乳腺中外侧斜视图的中央乳腺组织周围的感兴趣区域来测量的。计数密度表示为施用活性的cts / cm 2 / MBq。计算Spearman相关系数(rs)。结果:共分析200例患者。任何注射均未怀疑剂量渗透。平均管理活动量为292 MBq(标准差,13.8 MBq;范围为247-326 MBq)。平均计数密度为7.2 cts / cm2 / MBq(标准差为2.7 cts / cm2 / MBq;范围为3.1–17.8 cts / cm2 / MBq)。 MBI计数密度与身高(rs =?0.18; P = 0.01),体重(rs =?0.23; p = <0.001),体重指数(rs =?0.16; P = 0.02),体表面积呈弱负相关。 (rs = 0.22; P = 0.002),LBMJames(rs = 0.23; P = 0.001)和LBMJanma(rs = 0.23; P = 0.001)。在计数密度与乳房厚度之间未发现相关性(rs = 0.06; P = 0.37)。结论:我们的结果表明,在乳房组织中摄取99mTc-司他他比与身体大小或受压乳房厚度之间缺乏联系。对于较大的患者,可能有必要从标准的300 MBq的活动量更改为标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号